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Objectives: HIV/AIDS prevalence in Colombia is 0,8%. Currently for the country 
is important to assess the effectiveness and impact of its practices on the health 
of its population. A health maintenance organization (HMO) with national cover-
age aims to contribute by assessing the health outcomes of its care program for 
HIV/AIDS patients, a high cost disease with great impact on HRQOL. To evaluate the 
cost-effectiveness of the care program for HIV/AIDS patients insured by a HMO in 
Colombia, comparing its results in three health care providers (HCP). MethOds: A 
Markov model in MS Excel® was built to represent the natural history of HIV/AIDS 
based on the staging of the disease given by WHO according to the CD4 lymphocytes 
level. Direct costs were included, according to the information available on HMO´s 
databases. The outcome measure were QALY’s taken from the literature. Transition 
probabilities were calculated from tracking a cohort of 884 HIV/AIDS patients over 
18 years old, from three health providers (HCP A, B and C) in 7 cities across the coun-
try, during 2011 and 2012. Time horizon was lifetime. Perspective was third payer. 
Deterministic and probabilistic sensitivity analysis were performed. Results: HCP 
C was dominated. HCP A versus HCP B ICER was USD$2.497 per life year gained and 
USD$3.674 per QALY. Annual average cost per patient by stage was: stage 1 USD$2.347, 
USD$2.281 stage 2, stage 3 USD$3.022, USD$4.103 stage 4 and USD$6.994 for stage 
5. cOnclusiOns: Given a willingness to pay 1 GDP per capita for the country, the HCP 
B is a very cost-effective option. The average annual cost of patients in stage 5 is three 
times stage 1. PRiMARy Funding sOuRce: health maintenance organization (HMO).
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Objectives: Breast magnetic resonance imaging (MRI) is a sensitive method of 
breast screening and is increasingly being used for detection of breast cancer among 
high risk young women. However, the specificity of breast MRI is relatively low and 
costs are quite high. The purpose of this study was to determine if breast MRI is 
a cost-effective approach for the detection of breast cancer among young women 
at high risk. MethOds: A Markov model was built up to compare annual breast 
cancer screening with either breast MRI or mammography among young women 
who have more than 15% lifetime risk of breast cancer. Data from published studies 
provided probabilities for the model inputs. All costs and benefits were discounted 
at 5% per year. The analysis was performed from societal perspective with results 
reported in 2013 U.S. dollars. One-way and net benefits sensitivity analyses addressed 
uncertainty in model parameters. Results: Breast MRI provided 19.38 discounted 
quality-adjusted life-years (QALYs) at a discounted cost of $37,765 while mam-
mography provided 19.14 QALYs at a cost of $23,226 over 30 years of screening. The 
incremental cost-effectiveness ratio of breast MRI compared to mammography was 
$59547/QALY. In one-way sensitivity analysis and net benefits sensitivity analysis, the 
cost-effectiveness or net benefits of MRI screening depends critically on the accuracy 
of both MRI and mammography. cOnclusiOns: Annual MRI screening of women 
who have more than 15% lifetime risk of breast cancer was found to be potentially 
cost-effective, with an ICER of $59547/QALY when compared to annual mammography 
alone. The benefits of early detection of breast cancer with MRI in this population may 
outweigh the added cost of screening and the higher risk of false positives. However, 
the cost-effectiveness of MRI screening is highly dependent on the accuracy of MRI 
and Mammography. There remains some statistical uncertainty around this result.
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Objectives: Untreated syphilis in pregnancy is associated with adverse clinical 
outcomes to the infant. In low and middle income countries in Asia, roughly one 
out of three women is not tested for syphilis during pregnancy. The objective of 
this analysis was to evaluate the cost-effectiveness, budget impact, and potential 
reduction in adverse pregnancy outcomes of antenatal syphilis screening using 
the recently introduced point of care immunochromatographic strip (ICS) test for 
11 select countries in Asia. MethOds: A previously published cost-effectiveness 
model was adapted to reflect the perspectives of the respective national health 
care systems. Clinical outcomes of infants born to syphilis-infected mothers on 
the endpoints of stillbirth, neonatal death and congenital syphilis were obtained 
from published sources. Treatment was assumed to consist of three injections of 
benzathine penicillin. Country-specific inputs included the antenatal prevalence 
of syphilis; annual number of live births; proportion of women with at least one 
antenatal care visit; per capita gross national income and estimated hourly nurse 
wages. Results: In all 11 Asian countries, syphilis screening is highly cost-effec-
tive with an weighted average cost/DALY averted of US$82 (range: US$22-US$518). 
Universal screening may reduce the annual number of stillbirths by up to 10,000, 
neonatal deaths by up to 4,000, the annual incidence of congenital syphilis by up to 
5,000 and avert up to 450,000 DALYs at an incremental annual direct medical cost of 
US$23.0 million. Due to its low screening rate of 0.1%, Indonesia accounts for almost 
50% of DALYs that could be averted. In contrast, Laos, Malaysia, and Thailand are 
close to universal screening and leave little room for improvement. cOnclusiOns: 
The use of ICS tests for antenatal syphilis screening is highly cost-effective in low 
and middle income countries in Asia. Antenatal programs should either expand or 
maintain full access to syphilis screening using the ICS test.
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obtained from published literature. Resource utilization and costs associated with 
managing vision loss and eye examination were obtained from Health PEI, Ontario 
Ministry of Health and Long-term Care, and published literature. A decision analytic 
model was used to estimate an incremental cost-effectiveness ratio (ICER). Costs 
were expressed in 2012 Canadian dollars. A series of sensitivity analyses, including 
one-way and two-way sensitivity analyses, was performed to assess the possible 
uncertainty and robustness of our findings. Results: Compared with non-insured 
eye examination, insured eye examination for PEI residents led to an annual gain of 
0.01 quality adjusted life year (QALY) and an incremental cost of $5.52 per person, 
yielding an ICER of $2,785 per QALY. Sensitivity analyses showed that cost-effective 
estimates were highly sensitive to the incidence of vision loss, rate of eye examination 
by optometrists, and utility of vision loss. Specifically, higher incidence of vision loss 
and greater rate of eye examination by optometrists offered lower cost-effectiveness 
ratios. cOnclusiOns: Insured eye examination for PEI residents was a highly cost-
effective option compared to non-insured eye examination. This intervention was 
even more cost-effective if greater proportion of PEI residents received the eye exami-
nation by optometrists and if the incidence of vision loss in PEI increased.
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Objectives: Clinic evidence shows that nephroprotection programs in patients 
with chronic kidney disease improve patient’s health, life expectancy and reduce 
hospitalizations and early deaths. In Mexico, there are few nephroprotection 
programs. The purpose of this study was to analyze a nephroprotection program 
in patients of the Mexican Institute of Social Security with chronic kidney dis-
ease aimed to improve life expectancy and to reduce hospitalizations and early 
deaths. MethOds: The study design was a cost-effectiveness analysis from the 
governmental perspective. All the costs were obtained from the Diagnosis-related 
groups that Mexican Institute of Social Security publishes. Costs were expressed 
in 2013 constant USD. A Markov model with forty eight monthly cycles was used. 
We considered five chronic kidney disease stages according to US National Kidney 
Foundation and also death stage. Parameters were obtained from other nephropro-
tection programs and also from the Mexican Institute of Social Security statistics. 
Years life gained, hospitalizations and early deaths avoided ICER were estimated 
and discounted at 5% annual rate. Univariate sensitivity analysis for costs was 
performed. Also we conducted budget impact analysis. Results: The nephro-
protection program was cost-saver for cost per year life gained (ICER= $-1,477) 
and for hospitalizations avoided (ICER= $-4,984) and cost-effective for early death 
avoided (ICER= $22,738). The program increases thirteen months life expectancy, 
reduces 50% hospitalizations and avoids 21,118 deaths in a four-year horizon. The 
hospitalizations avoided also allow increasing hospital supply in 67%. The budget 
impact analysis showed that the program could achieve savings of 42% for the 
Institute. cOnclusiOns: The nephroprotection program could improve patient’s 
health and reduce disease progression, therefore, it could be considered for imple-
mentation in the Mexican Institute of Social Security.
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Objectives: The follow-up rate among children with vision problems in our out-
reach programs has been poor (< 5%). We therefore developed the Children’s Eye 
Care Adherence Program (CECAP) for Philadelphia school children, a social worker 
(SW) intervention to address barriers to care among children with significant vision 
problems. The objective of this study was to measure CECAP’s effectiveness and cost. 
We also sought to identify barriers to care through a conceptual framework and 
geomapping software. MethOds: CECAP included SW review of records to identify 
children needing follow-up. SW phoned families to identify and resolve barriers to 
eye care and scheduled appointment. Effectiveness was defined as the percent com-
pleting ≥ 1 follow-up visit within the physician-recommended time frame. Cost was 
measured using SW time logs (converted to costs using SW wage rates + benefits) 
and additional materials (forms, postage, phone charges). Barriers were organized 
into a conceptual framework depicting 3 main themes (predisposing factors, system 
factors, and ability to pay) and mapping software to visually illustrate follow-up 
rate. Results: Of 1200 patients, 120 required follow-up ophthalmic care in 2012-
13. 71 patients were reached and completed a follow-up (59.2%); 49 patients were 
reached but did not follow-up (40.8%). SW time was ~3hrs/patient for those who 
followed up and ~2hrs/patient for those that did not. Based on the CECAP program 
total cost ($14,249) and the reimbursement payment ($6,265.66), the net cost of 
the CECAP program was $7,983.59. Predisposing factors (lack of awareness, level of 
perceived importance, conflict of commitment, lack of means of communication) 
was the primary barrier theme for patients that did not follow-up. cOnclusiOns: 
CECAP significantly improved adherence to eye care but comes at an additional 
cost. Future efforts should focus on reducing operational efficiencies (e.g., capping 
outreach attempts) and targeting CECAP based on predictors of follow-up.
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diabetes-related complications resulting in improved quality of life and increased 
survival rates.
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Objectives: In spite of the national screening program, evidence is lacking on the 
health benefits such as decrease in complications and cost of screening of diabetes. 
Little is known about cost-effectiveness of national diabetes screening program. 
The purpose of this study is to evaluate cost-effectiveness of the current national 
screening program of type 2 diabetes in South Korea. MethOds: A Markov model 
for type 2 diabetes that reflected current national screening program was developed. 
This model analyzed the effects of screening for the population aged 40 and older 
with first and second FPG (fasting plasma glucose) tests. Data sources for the model 
parameters included the National Health and Nutrition Examination Survey data 
for cohort characteristics, the National Health Insurance claims data (HIRA-NPS) for 
costs, and published literature for other epidemiology data, treatment effects and 
utility pertaining to diabetes patients. From a payer’s perspective, cost per life-year 
gained (LYG) and cost per quality-adjusted life-year (QALY) gained from screening 
compared with no screening were calculated based on lifetime costs and accumu-
lated LYGs and QALYs. One-way sensitivity analyses were carried out. Results: The 
incremental cost-effectiveness ratio (ICER) was higher than 84 million KRW per LYG 
and higher than 94 million KRW per QALY. The superior strategy in screening inter-
val was identified as every two year. The results of sensitivity analysis showed that 
older age, higher participation rates of second FPG test, and higher rates of glucose 
control could improve cost-effectiveness of diabetes screening. cOnclusiOns: The 
current national diabetes screening program was not cost-effective considering GDP 
per capita or willingness-to-pay per QALY. Policies to improve participation rates 
in second screening test need to be established since higher second screening rate 
leads to positive impacts on ICER and screening interval. Also, effective diabetes 
management program for diagnosed patients after screening is required as glucose 
control is related to ICER improvement.
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Objectives: Endometriosis is a gynecological disease that affects the quality of life 
of women of reproductive age and is costly to treat. The purpose of the review was 
to determine if early detection of endometriosis reduces the costs and increases the 
effectiveness of endometriosis treatment. MethOds: We systematically reviewed 
studies published from 1996 to 2012. We evaluated two interventions (medical & 
surgical) of endometriosis with two outcomes (reduced costs & increased success/
reduced recurrence time). We compared the outcomes of early (minimal & mild) 
and late (moderate & severe) stage interventions of endometriosis by summarizing 
the studies and listing their relative main outcomes. We also assessed the qual-
ity of the studies by checking (yes or no) whether they conducted a sensitivity 
analysis. Results: Seven studies met the inclusion criteria of enrolling patients 
suffering from endometriosis and reporting costs and effects relating to detection 
and treatment of early and late stage of endometriosis. Early stage interventions are 
less costly and more effective but only two studies conducted a sensitivity analy-
sis. cOnclusiOns: The findings indicate that early detection of endometriosis 
improves the outcomes of endometriosis treatment (both medical and surgical) but 
there are limitations to these findings. The methodological structure of the studies 
was not conformed to analytical robustness and therefore affected the quality of 
results and outcomes reported. This validates the World Endometriosis Research 
Foundation’s recommendation for more high-quality studies on the economic evalu-
ation of endometriosis.
PHS62
CoSt EffECtivEnESS analySiS of Hiv and aidS trEatMEnt in kEnya: 
a CoMParativE Study of MBagatHi diStriCt and Moi tEaCHing and 
rEffEral HoSPitalS
Owiti EA
The University of Nairobi, Nairobi, Kenya
Objectives: HIV and AIDS is a major cause of premature death and impose a large 
disease burden in Kenya. Antiretroviral treatment (ART) is one of the interventions 
being implemented to mitigate these impacts. Economic studies on the cost and 
health effects of ART are very scarce in developing countries, Kenya included. The 
objectives of this research were to estimate health care utilization, the unit costs of 
services and the cost per life year (LYs) gained of HIV treatment interventions from 
a provider’s perspective. MethOds: A retrospective study of adults on ART and 
those not on ART, had CD4 counts 250 and below at enrolment. Data was collected 
from Mbagathi District Hospital (Mbagathi) (n= 350) and Moi Teaching and Referral 
Hospital (Moi) in Kenya (n= 400). A micro-costing method was used to cost all the 
treatment inputs and Markov modelling estimated the cost-effectiveness analysis, 
lifetime costs and health benefits of HIV treatments in the two hospitals. Results: 
The undiscounted lifetime costs for No-ART in Mbagathi and Moi were, KSh169,123 
($2,260) and KSh184,415 ($2,464) respectively, while life years gained for both hospi-
tals was 2.68 years. The undiscounted lifetime costs for the ART group in Mbagathi 
and Moi were KSh932,071 ($1,245) and KSh1,608,496 ($21,490) respectively while life-
time benefits were 15.85 and 25.56 years for Mbagathi and Moi respectively. At 10% 
discounting rate, the lifetime benefits for No ART for both hospitals was 2.1 years 
and costs were KSh153,807 ($2,055) and KSh166,377 ($2,223) for Mbagathi and Moi 
respectively while the lifetime cost for ART was KSh423,959 ($5,664) and KSh563,647 
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Objectives: Multiple Sclerosis (MS) disease treatment requires high adherence 
levels to maximize medicine effectiveness. It has been shown that comprehensive 
care at home programs in MS improve treatment adherence. In Mexico, average 
adherence levels for MS is less than 80%, therefore, the purpose of this study was 
to evaluate a comprehensive care at home program in patients of the Mexican 
Institute of Social Security with Multiple Sclerosis aimed to improve treatment 
adherence and to increase life expectancy. MethOds: The study design was a cost-
effectiveness analysis from the governmental perspective. The costs for patient 
care were obtained from the Diagnosis-related groups that Mexican Institute of 
Social Security publishes and drugs costs were obtained also from the Institute. 
Costs were expressed in 2013 constant USD. A Markov model with sixty monthly 
cycles was developed. Based on the Expanded Disability Status Scale, we divided 
the model into six possible stages (4 EDSS stages, 2 for relapses according to EDSS 
stage) and death. We analyzed six different medicines (intramuscular interferon 
beta 1a, subcutaneous interferon beta 1a, subcutaneous interferon beta 1b, glati-
ramer acetate, Natalizumab and Fingolimod. Parameters were obtained from MS 
literature in Mexico. ICER per year life gained was estimated and discounted at 5% 
annual rate. Results: The comprehensive care at home program increases life 
expectancy in a range of 6 to 12 months depending on the medicine we were analyz-
ing. ICER is cost-effective ($ 556) in a five-year horizon. The program could increase 
adherence in more than 20 percentage points in the best scenario. cOnclusiOns: 
The comprehensive care at home program could improve patient’s health and qual-
ity of life through increasing treatment adherence, therefore it could be considered 
for implementation beyond the Mexican institute of Social Security.
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Objectives: Hospital care at home programs could improve patient’s health and 
also reduce health system costs. In Mexico, there are few programs that offer this 
service. The purpose of this study was to analyze a hospital care at home program 
in patients of the Mexican Institute of Social Security in Mexico City aimed to avoid 
nosocomial infections and hospital readmissions. MethOds: The study design was 
a cost-effectiveness analysis from the governmental perspective. We considered 540 
potential patients. Through a decision tree model two scenarios were compared: 
1. Inpatient Hospital Care vs. 2. Hospital care at home. First scenario costs were: 
hospitalization (per day) and nosocomial infection. Second scenario cost considered 
was hospital at home care (per day). Both scenarios considered hospital readmission 
costs. All the costs were obtained from the Mexican Institute of Social Security and 
were expressed in 2013 constant USD. Effectiveness parameters were obtained from 
similar programs in Mexico and Spain. As effectiveness measures we considered: 
nosocomial infection avoided, hospital readmission avoided and death avoided in 
a one-year horizon. Univariate sensitivity analysis for costs was performed. We 
estimated the hospital supply extension through bed days avoided. Also budget 
impact analysis was conducted. Results: Hospital care at home program reduces 
21% nosocomial infection, 48% hospital readmission and 5% deaths. The program is 
very cost-effective for nosocomial infection avoided (ICER = $2,435), cost-saver for 
hospital readmission (ICER = $ -1,674) and cost-effective for death avoided (ICER = 
$ 15,223). Hospital supply extension is 1,620 beds per year. Budget impact analysis 
showed that nephroprotection could generate savings of 25% depending on the 
Hospital at home care cost per day. cOnclusiOns: Hospital care at home improve 
patient’s Health, reduces health system costs and expands hospital supply, there-
fore, it could be considered for implementation in our country.
PHS59
CoSt-EfECtivEnESS analySiS of inSulin glarginE (lantuS) initiation 
By PHarMaCiStS in a Canadian SEtting: tHE rxing Study
Al Hamarneh Y.1, Sauriol L.2, Tsuyuki R.1, Brown S.T.3
1University of Alberta, Edmonton, AB, Canada, 2Sanofi, Laval, QC, Canada, 3Ethicon, Inc, 
Somerville, NJ, USA
Objectives: Type 2 diabetes is a progressive disease with 50% loss in insulin-
producing capacity at time of diagnosis, with an average 5% annual thereafter. 
Therefore, many patients with type 2 diabetes (T2DM) require insulin treatment. 
Pharmacists are frontline health care professionals who see patients with T2DM 
frequently and as such they could help them achieve their targets by intervening 
in timely manner. The RxING study assessed the effect of a community pharmacist 
intervention in uncontrolled patients with T2DM treateted with oral hypoglycemic 
agents. Those patients were prescribed insulin glargine and followed up for 26 weeks 
by their pharmacist. At endpoint, the average A1c reduction was 1.8% (95%CI 1.4 to 
2). The objective was to assess the cost-effectiveness of having pharmacists’ early 
intervention in prescribing insulin. MethOds: The IMS CORE Diabetes Model, a 
Markov structure and Monte Carlo simulation model was used to assess compli-
cations and disutilities. Health utility and cost data were obtained from recently 
published Canadian publications. The efficacy of insulin in terms of HbA1c reduction, 
and corresponding rates of hypoglycemia were obtained from the RxING study. The 
base case analyses examined the effects of having pharmacist prescribe insulin 
1, 2 and 3 years earlier than a physician. Results: Having pharmacists prescribe 
insulin 1 year earlier than a physician resulted in an incremental cost savings of 
$790 (CDN$) and a gain of 0.048 QALYs per patient. Early pharmacist prescription of 
insulin by 2 years resulted in an increment cost savings of $687 (CDN$) and a gain 
of 0.075 QALYs per year. At 3 years earlier the results were a cost savings of $105 
and a gain of 0.086 QALYs. cOnclusiOns: Having pharmacists initiate insulin 
sooner in uncontrolled T2DM results in cost-savings and delays the development of 
